50-State Survey of Telehealth Insurance Laws
Access Evolution: Post-Public Health Emergency Advances in Telehealth Laws Make Seeking Medical Care Easier for Many
May 6, 2024
Patients and health care professionals have been quick to adopt telemedicine and digital health technologies. In the last five years, the legal landscape for telehealth insurance coverage and reimbursement has expanded in several ways:
- More organizations are implementing and expanding robust virtual care programs to supplement their traditional in-person offerings.
- In rural areas, phone coverage helps those with limited access to broadband internet and in-person care.
- With telehealth and digital health resources, patients also get a boost in mental health care because these tools help address the imbalance in supply and demand.
- More states changed their laws to prohibiting exclusive telehealth platform arrangements, increasing competition among software companies and allowing individual clinics and hospitals to make decisions based on what works for them and their patients.
- There has been progress with payment parity — reimbursing providers at the same rate for telehealth as in-person, but there is still a way to go.
All of this together is steady progress, and it codifies by law improvements that patients have loved. Unfortunately, the market cannot rely on the health care industry to make these changes voluntarily — the laws passed by individual states serve as the bridge to solidify telehealth-based services as a core health insurance benefit for the patients who use them.
Disclaimer
This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.
State Telehealth Insurance Laws 2019 vs. 2024
Author(s)
Related Insights
April 23, 2026
Health Care Law Today
DEA Issues Long Awaited Final Order Rescheduling Certain Marijuana Products to Schedule III: What It Means, What It Doesn’t, and What Comes Next
Effective April 22, 2026, the Acting Attorney General issued a final order placing certain categories of marijuana and marijuana products into Schedule III of the Controlled Substances Act (“CSA”) in accordance with President Trump’s December 18, 2025 Executive Order on Increasing Medical Marijuana and Cannabidiol Research. This is a landmark development in federal drug policy and one that carries significant legal and business consequences for entities in the pharmaceutical, cannabis, healthcare, tax, and regulatory compliance sectors. As with most everything touching marijuana, however, the details matter enormously. Importantly, the Final Order does not broadly reclassify marijuana. Instead, it defines a narrow and conditional rescheduling that includes several important caveats, added steps, and ongoing obligations that affected parties must understand.
April 20, 2026
Health Care Law Today
New Federal Focus on Fraud, Waste and Abuse May Signal Changes for the Health Care Industry
Congress and the Trump Administration have issued a series of heightened warnings indicating an emerging effort to crack down on what it terms rampant “fraud, waste, and abuse” in the health care industry. All industry stakeholders should be aware of this new focus, which not only signals potentially heightened scrutiny and enhanced penalties for compliance issues but also potential policy changes intended to reduce federal expenditures on programs or practices that are identified as improper or wasteful.
April 14, 2026
Health Care Law Today
FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products
On April 1, 2026,the U.S. Food & Drug Administration (FDA) issued a statement clarifying its compliance policy on the conditions that must be met for compounded drugs to qualify for the exemptions under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).